

Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer

Ying Chen,[†] Catherine A. Foss,[†] Youngjoo Byun,[†] Sridhar Nimmagadda,[†] Mrudula Pullambhatla,[†] James J. Fox,[†] Mark Castanares,[‡] Shawn E. Lupold,[§] John W. Babich,^{||} Ronnie C. Mease,[†] and Martin G. Pomper^{*,†,‡}

Russell H. Morgan Department of Radiology and Radiological Sciences, Department of Pharmacology & Molecular Sciences, Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts 02142

Received August 24, 2008

To extend our development of new imaging agents targeting the prostate-specific membrane antigen (PSMA), we have used the versatile intermediate 2-[3-(5-amino-1-carboxy-pentyl)-ureido]-pentanedioic acid (Lys-C(O)-Glu), which allows ready incorporation of radiohalogens for single photon emission computed tomography (SPECT) and positron emission tomography (PET). We prepared 2-[3-[1-carboxy-5-(4-[¹²⁵I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid ([¹²⁵I]**3**), 2-[3-[1-carboxy-5-(4-[¹⁸F]fluoro-benzoylamino)-pentyl]-ureido]-pentanedioic acid ([¹⁸F]**6**), and 2-(3-[1-carboxy-5-[(5-[¹²⁵I]iodo-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pentanedioic acid ([¹²⁵I]**8**) in 65–80% (nondecay-corrected), 30–35% (decay corrected), and 59–75% (nondecay-corrected) radiochemical yields. Compound [¹²⁵I]**3** demonstrated 8.8 ± 4.7% injected dose per gram (%ID/g) within PSMA⁺ PC-3 PIP tumor at 30 min postinjection, which persisted, with clear delineation of the tumor by SPECT. Similar tumor uptake values at early time points were demonstrated for [¹⁸F]**6** (using PET) and [¹²⁵I]**8**. Because of the many radiohalogenated moieties that can be attached via the ε amino group, the intermediate Lys-C(O)-Glu is an attractive template upon which to develop new imaging agents for prostate cancer.

Introduction

Prostate cancer (PCa^a) is the second leading cause of cancer-related death in men.¹ Localization of tumor as well as determination of the total body burden of PCa have important implications for therapy, particularly as new combination and focal therapies become available. Also critically needed are targeted agents that can provide a readout on the biology of the tumor, with the ability to predict which will lie dormant and which will develop into aggressive, metastatic disease. The current clinical standard for localizing cancer, including PCa, is shifting from the anatomic techniques of computed tomography (CT) and magnetic resonance (MR) imaging to more physiologically relevant methods that employ molecular imaging, such as MR spectroscopy,² single photon emission computed tomography (SPECT), and positron emission tomography (PET).^{3,4} Those newer methods, which utilize molecular imaging, may provide the biological readout necessary for under-

standing tumor physiology, enabling more accurate prognosis and therapeutic monitoring.

Because of the relatively low metabolism of PCa, PET with [¹⁸F]fluorodeoxyglucose (FDG-PET) has proved ineffectual in this disease. Other promising, experimental radiopharmaceuticals for imaging PCa are emerging, including those of the choline series,^{5–9} radiolabeled acetates,¹⁰ anti-1-amino-3-[¹⁸F]fluorocyclobutyl-1-carboxylic acid (anti-[¹⁸F]F-FACBC),^{11,12} 1-(2-deoxy-2-[¹⁸F]fluoro-L-arabinofuranosyl)-5-methyluracil ([¹⁸F]F-MAU),¹³ and [¹⁸F]fluorodihydrotestosterone ([¹⁸F]FDHT).¹⁴ Each has its benefits and detriments, with no single agent ideal, i.e., easy to synthesize, little metabolism, and demonstrating tumor-specific uptake, in all PCa phenotypes.

Overexpressed on most solid tumor neovasculature¹⁵ as well as in prostate cancer, the prostate-specific membrane antigen (PSMA) is becoming an attractive target for cancer imaging and therapy.^{16,17} ProstaScint is an ¹¹¹In-labeled monoclonal antibody against PSMA that is clinically available for imaging PCa.¹⁸ ProstaScint and radiolabeled variations of this antibody are fraught with long circulation times and poor target to nontarget tissue contrast, limiting the utility of these agents.^{19–21} Previously, we reported the synthesis of several low molecular weight, urea-based PSMA inhibitors for imaging PCa. Those compounds include *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-[¹¹C]methyl-L-cysteine ([¹¹C]DCMC),²² *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-3-[¹²⁵I]iodo-L-tyrosine ([¹²⁵I]DCIT),²³ *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-4-[¹⁸F]fluorobenzyl-L-cysteine ([¹⁸F]DCFBC),²⁴ and [^{99m}Tc](2-pyridylmethyl)₂N(CH₂)₄CH-(CO₂H)NHCO-(CH₂)₆CO-NH-lys-NH-CONH-glu) ([^{99m}Tc]L1)²⁵ (Figure 1). Here we report the molecular modeling, radiosynthesis, in vitro PSMA inhibitory potency, tissue uptake selectivity, and preclinical imaging of the latest compounds in our series of low molecular weight agents for imaging PCa. Those agents include: 2-[3-[1-carboxy-5-(4-[¹²⁵I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic acid

* To whom correspondence should be addressed. Phone: 410-955-2789. Fax: 443-956-5055. E-mail: mpomper@jhmi.edu. Address: Johns Hopkins Medical Institutions, 1550 Orleans Street, 492 CRB II, Baltimore, MD 21231.

[†] Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Medical Institutions.

[‡] Department of Pharmacology & Molecular Sciences, Johns Hopkins Medical Institutions.

[§] Department of Urology, Johns Hopkins Medical Institutions.

^{||} Molecular Insight Pharmaceuticals, Inc.

^a Abbreviations: PSMA, prostate-specific membrane antigen; GCPII, glutamate carboxypeptidase II; NAAG, *N*-acetylasparylglutamate; NAALADase, *N*-acetylated-α-linked acidic dipeptidase; DCMC, *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-methyl-L-cysteine; DCIT, *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-3-iodo-L-tyrosine; DCFBC, *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-4-fluorobenzyl-L-cysteine; DCL, *N*-[*N*-[(*S*)-1,3-dicarboxypropyl]carbamoyl]-(*S*)-L-lysine; L1, (2-pyridylmethyl)₂N(CH₂)₄-CH(CO₂H)NHCO-(CH₂)₆CO-NH-lys-NHCONH-glu; 2-PMPA, 2-(phosphonomethyl)pentanedioic acid; SPECT, single photon emission computed tomography; PET, positron emission tomography; PCa, prostate cancer; SD, standard deviation.




Figure 1. Radiolabeled PSMA inhibitors.

([^{125}I]**3**), 2-[3-[1-carboxy-5-(4-[^{18}F]fluorobenzoylamino)-pentyl]-ureido]-pentanedioic acid ([^{18}F]**6**), and 2-(3-[1-carboxy-5-[(5-[^{125}I]iodo-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pentanedioic acid ([^{125}I]**8**).

Results and Discussion

Design of PSMA Inhibitors. As mentioned above, we previously reported SPECT and PET imaging probes of urea-based PSMA inhibitors including [^{125}I]**DCIT**, [^{11}C]**DCMC**, [^{18}F]**DCFBC**, and [$^{99\text{m}}\text{Tc}$]**L1**.


[^{125}I]**DCIT** is a derivative of a tyrosine-glutamate urea, whereas [^{11}C]**DCMC** and [^{18}F]**DCFBC** are derivatives of a cysteine-glutamate urea. Compound [$^{99\text{m}}\text{Tc}$]**L1** consists of Lys-C(O)-Glu to which a chelate at the terminus of a linker moiety has been attached. In this work, we chose to investigate further derivatives of Lys-C(O)-Glu in order to (1) take advantage of the many radiohalogenation methods and radiohalogenated prosthetic groups developed previously for reaction with the ε -amino group of lysine residues²⁶ and (2) increase the structural diversity of this class of PSMA inhibitors. We accordingly designed the syntheses of **3**, **6**, and **8** to utilize the tri-*p*-methoxybenzyl (tri-PMB) ester of 2-[3-(5-amino-1-carboxypentyl-ureido)]-pentanedioic acid as a common starting material.

Chemistry

Synthesis. The synthesis of **3**, **6**, and **8** are shown in Schemes 1, 2, and 3, respectively. *N*-hydroxysuccinimidyl-4-iodobenzoate²⁷ and *N*-hydroxysuccinimidyl-4-fluorobenzoate²⁸ were reacted with the tri-PMB ester of Lys-C(O)-Glu **1**²⁵ to provide **2** (Scheme 1) and **5** (Scheme 2), respectively. The PMB groups were then removed using trifluoroacetic acid (TFA)/anisole to yield compounds **3** and **6**, respectively. *N*-Hydroxysuccinimidyl-5-(tri-*n*-butylstannyl)-3-pyridinecarboxylate²⁹ was reacted with **1** to give **7** (Scheme 3), followed by iododestannylation and ester cleavage to give **8**.


Modeling of Inhibitors in the Active Site of PSMA. Recently determined GCPII (PSMA) crystal structures made it possible to perform structure-based molecular modeling studies with **3**, **6**, and **8**.^{30–32} An X-ray structure of PSMA complexed with 2-PMPA (PDB ID: 2PVW) was used for modeling due to the high resolution of this structure (1.71 Å) and the small number of missing amino acid residues.³² Interestingly, PSMA exists in two conformations including a “binding” conformer and a “stacking” conformer in the arginine-rich region (S1-binding pocket) of the active site.³³ We carried out docking studies of **3**, **6**, and **8** with both conformers using a CHARMM-based CDOCKER module implemented in Discovery Studio 2.0 (Accelrys Inc., San Diego, CA).³⁴ Details of that procedure

Scheme 1^a




^a (a) *N*-hydroxysuccinimidyl-4-iodobenzoate, triethylamine, CH_2Cl_2 ; (b) TFA, anisole; (c) *N*-hydroxysuccinimidyl-4-tributylstannylbenzoate, triethylamine, CH_2Cl_2 ; (d) [^{125}I]NaI, *N*-chlorosuccinimide, HOAc, MeOH; (e) TFA, anisole.

Scheme 2^a



^a (a) *N*-hydroxysuccinimidyl-4-fluorobenzoate, triethylamine, CH_2Cl_2 ; (b) TFA, anisole; (c) *N*-hydroxysuccinimidyl-4-[^{18}F]fluorobenzoate, triethylamine, CH_2Cl_2 ; (d) TFA, anisole.

are available in the Supporting Information. Analysis of the docked poses demonstrated that potential binding modes of the three compounds were very similar to that of 2-PMPA, showing that the glutamate moiety of the three compounds completely overlapped with the pentanedioic acid moiety of 2-PMPA, irrespective of which conformer was under study (Figures 1 and 2 in the Supporting Information). The only differences among the three compounds with respect to their binding to either conformer were observed in the arginine patch. The

Scheme 3^a

^a (a) *N*-hydroxysuccinimidyl-5-(tri-*n*-butylstannyl)-3-pyridinecarboxylate, triethylamine; CH₂Cl₂; (b) NaI, *N*-chlorosuccinimide, HOAc, MeOH; (c) TFA, anisole; (d) [¹²⁵I]NaI, *N*-chlorosuccinimide, HOAc, MeOH; (e) TFA, CH₂Cl₂.

subpocket generated by three arginines (Arg 463, 534, and 536) in the binding conformer can accommodate the 4-fluorophenyl substituent completely and the 4-iodophenyl and 5-iodo-3-pyridyl groups partially, while all three projected into the tunnel region when docked with the stacking conformer. CDOCKER scores of the best poses with the binding conformer of PSMA (83.177 for **3**, 83.172 for **6**, 87.610 for **8**) were higher than those with the stacking conformer (82.193 for **3**, 75.32 for **6**, 78.134 for **8**), indicating that the binding conformer of PSMA likely generates a more stable complex with **3**, **6**, and **8** than does the stacking conformer.

We also resolved the PSMA crystal structure complexed with **3** (PDB ID: 3D7H). Details of PSMA cocrystallized with **3**, as well as with other urea-based PSMA inhibitors such as DCIT, DCMC, and DCFBC, are described elsewhere (in press). As predicted from modeling studies, only the binding conformation of the arginine patch region was found in PSMA complexed with **3**. To elucidate potential binding modes of the other two compounds (**6** and **8**), we carried out docking studies using the 3D coordinates of 3D7H in the presence or in the absence of water molecules in the active site. The best poses of **3**, **6**, and **8** from the docking studies using the CDOCKER module are shown in Figure 2a, overlaid with crystal ligand, i.e., the compound as it is cocrystallized with PSMA, of **3**. As shown in Figure 2a, all of the radionuclide-bearing moieties (4-iodophenyl, 4-fluorophenyl, and 5-iodo-3-pyridyl) were located within the arginine patch of the S1 binding site. 4-Iodophenyl and 4-fluorophenyl groups protruded deeply within the subpocket compared to the 5-iodo-3-pyridyl moiety. CDOCKER scores of the three poses are ordered **3** (80.63) > **6** (72.39) > **8** (69.78). Detailed polar interaction of crystal ligand **3** and the best poses of **6** and **8** with PSMA are available in the Supporting Information. The cationic sidechains of Arg 463 and Arg 534 provide cation- π interactions with the aromatic rings of **3**, **6**, and **8**, leading to stabilization of the ligand within the subpocket. Docking results of PSMA without water molecules in the active site showed that the radionuclide-bearing moieties of **6** and **8** were outside of the subpocket and projected into the tunnel

region (Figure 2b), while the 4-iodophenyl group of **3** was projected into the subpocket. On the basis of in vitro PSMA inhibitory activities and molecular modeling studies, it appears that ligand interaction with the subpocket of the S1 binding site contributes more to binding affinity than does interaction with the tunnel region.

Radiochemistry. As shown in Scheme 1, [¹²⁵I]**3** was prepared via iododestannylation of the corresponding tri-*n*-butylstannyl precursor **4** followed by deprotection. The final product was obtained after purification by radio-high performance liquid chromatography (radio-HPLC). The radiochemical yield of this reaction ranged from 65–80% (*n* = 3). Specific radioactivity was >700 Ci/mmol (25.9 GBq/ μ mol).

The radiosynthesis of [¹⁸F]**6** is shown in Scheme 2. *N*-Hydroxysuccinimidyl-4-[¹⁸F]iodobenzoate ([¹⁸F]SFB) was prepared by the procedure of Chen et al.³⁵ [¹⁸F]SFB was reacted with **1**, followed by deprotection and purification by radio-HPLC to give [¹⁸F]**6**. The decay-corrected radiochemical yield of [¹⁸F]**6** ranged from 30–35% based on starting [¹⁸F]fluoride (*n* = 3). The mean synthesis time was 180 min from the time of addition of [¹⁸F]fluoride. Starting from 40 mCi of [¹⁸F]fluoride, the specific radioactivity of [¹⁸F]**6** was 250–300 Ci/mmol (9.1–11.1 GBq/ μ mol).

As shown in Scheme 3, [¹²⁵I]**8** was prepared using radioiododestannylation of the corresponding tri-*n*-butylstannyl precursor **7** followed by deprotection and purification by radio-HPLC. The radiochemical yields of this reaction ranged from 59–75% (*n* = 3). Specific radioactivity was >2000 Ci/mmol (74.0 GBq/ μ mol).

Biological Results

In Vitro Binding. The NAALADase inhibition assay was undertaken to determine the *K_i* value for **3**, **6**, and **8**.³⁶ The concentration of each compound was varied from 0.01 to 1000 nM against a fixed amount of [³H]NAAG (30 nM). The NAALADase (PSMA) was prepared from LNCaP cell lysates. The percentage of the enzymatic cleavage product, [³H]glutamate, produced was measured by scintillation counting and was plotted against the logarithmic concentration of the compound under study. Linear regression of the resulting data were solved for 50% [³H]glutamate production (50% inhibition) and resulted in *K_i* values of 0.010 nM for **3**, 0.256 nM for **6**, and 0.351 nM for **8** (Table 1). These results are similar to other compounds of this class.³⁷ Compounds **3**, **6**, and **8** were also evaluated using a fluorescence-based inhibition assay³⁷ as a second check on affinity and gave *K_i* values of 0.010, 0.194, and 0.557 nM, respectively.

Ex Vivo Biodistribution and Imaging. Compound [¹²⁵I]**3** was injected intravenously into severe-combined immunodeficient (SCID) mice bearing both PC-3 PIP (PSMA⁺) and PC-3 flu (PSMA⁻) xenografts. Table 2 outlines the ex vivo rodent tissue distribution results of [¹²⁵I]**3**. The blood, kidney, urinary bladder, spleen, and PSMA⁺ PC-3 PIP tumor display high uptake at the initial, 30 min postinjection (pi) time point. By 60 min pi, the uptake in PSMA⁺ PC-3 PIP tumor achieved its highest absolute value. The kidney achieved its maximal uptake at 24 h pi. The values noted in the kidney are largely due to specific binding rather than renal clearance due to the expression of high amounts of PSMA in the proximal renal tubule.^{38,39} The PSMA⁺ PC-3 PIP:kidney ratio remained constant (1:10) over 48 h. The spleen also exhibited high uptake (141 $\pm$ 14% ID/g) at 1 h, perhaps due to the presence of GCPIII, a close homologue of GCPII/PSMA.⁴⁰ We speculate that [¹²⁵I]**3** may bind to GCPIII as well as to GCPII, as demonstrated by several




Figure 2. (a) Overlay of the best poses for **3**, **6**, and **8** with the crystal ligand, i.e., **3**, as it is cocrystallized with PSMA (**3**, green), in the presence of water molecules in the active site of PSMA (PDB ID: 3D7H). (b) Overlay of the best poses (**3**, **6**, and **8**) with the crystal ligand (**3**, green) in the absence of water molecules in the active site of PSMA. Orange sphere (zinc ions), yellow spheres (chloride ion).

Table 1. PSMA In Vitro Inhibitory Activities and Calculated ClogD Values

compd	K_i [nM] ^a	SD ^b	K_i [nM] ^c	SD ^b	ClogD
3	0.010	0.003	0.010	0.004	-5.16
6	0.256	0.038	0.194	0.134	-5.64
8	0.351	0.257	0.557	0.265	-5.88

^a obtained from the NAALADase (radiometric) assay. ^b 95% confidence interval. ^c obtained from a fluorescence-based assay.

other PSMA ligands.⁴¹ However, unlike the kidneys, there was slow washout from the spleen over time. Urinary bladder uptake represents excretion at all time points, i.e., there was no specific binding to bladder wall. Tumor uptake indicated a high degree of specificity represented by the PSMA⁺ PIP:flu ratio of 11:1 at 60 min, rising to 140:1 at 48 h. Radiopharmaceutical uptake within tumor relative to other organs also increased with time, providing high PSMA⁺ PIP:organ ratios. We did not remove bone as part of our ex vivo assay, however, no bone uptake was noted on imaging (see below). Little metabolism for

compounds of this class has been demonstrated previously.^{22,25,24} We did not perform site-specific blockade studies, as we have previously proved the PSMA status of these tumor lines (PSMA⁺ PC-3 PIP and flu) by Western blotting (data not shown) and have other publications demonstrating PSMA-selective targeting and blockade in this model.^{23,25}

Compound [¹²⁵I]**3** was injected intravenously into a SCID mouse bearing both PSMA⁺ PC-3 PIP and PC-3 flu xenografts followed by SPECT-CT imaging. Figure 3 shows a SPECT-CT image of radiopharmaceutical uptake at 4 h pi. Note the intense uptake in the PSMA⁺ PC-3 PIP and absence of uptake in the PC-3 flu tumor. The small amount of radiopharmaceutical uptake seen in the liver, with no concurrent gastrointestinal uptake, is likely due to the hydrophilic nature of [¹²⁵I]**3** (ClogD = -5.16 at pH 7.4), and is consistent with the ex vivo biodistribution data. The very intense uptake in the kidneys is also consistent with the ex vivo biodistribution data.

Table 2. Ex Vivo Biodistribution of [125 I]3 in Tumor-Bearing Mice^{a,b}

	30 min	60 min	2 h	5 h	12 h	24 h	48 h
blood	0.9 ± 0.8 (10)	0.6 ± 0.2 (22)	0.3 ± 0.1 (36)	0.4 ± 0.2 (31)	0.1 ± 0.03 (125)	ND	ND
heart	2.7 ± 0.9 (3)	1.9 ± 0.3 (7)	1.4 ± 0.7 (8)	0.9 ± 0.2 (14)	0.5 ± 0.2 (25)	0.5 ± 0.2 (28)	0.1 ± 0.1 (100)
lung	5.8 ± 2.4 (1.5)	4.5 ± 0.5 (3)	3.6 ± 2.8 (3)	3.5 ± 0.6 (3.5)	2.6 ± 0.8 (5)	1.1 ± 0.8 (12)	0.5 ± 0.04 (22)
liver	7.7 ± 3.1 (1)	7.5 ± 0.8 (2)	5.9 ± 3.5 (2)	4.5 ± 1.0 (3)	1.4 ± 0.2 (9)	1.4 ± 0.6 (9)	0.7 ± 0.1 (16)
stomach	1.5 ± 0.9 (6)	1.5 ± 0.3 (9)	1.6 ± 1.5 (8)	0.8 ± 0.03 (15)	0.3 ± 0.06 (39)	0.7 ± 0.6 (18)	0.4 ± 0.2 (25)
pancreas	2.0 ± 0.3 (4)	2.3 ± 0.3 (6)	2.0 ± 0.7 (6)	1.6 ± 0.5 (8)	0.6 ± 0.2 (21)	1.2 ± 0.7 (11)	1.1 ± 0.6 (10)
spleen	83 ± 8 (0.1)	141 ± 14 (0.1)	104 ± 43 (0.1)	119 ± 9 (0.1)	69 ± 39 (0.2)	39 ± 6 (0.3)	22 ± 8.6 (0.5)
fat	4.5 ± 1.1 (2)	5.6 ± 1.0 (2)	6.2 ± 0.8 (2)	6.8 ± 1.3 (2)	3.8 ± 0.8 (3)	1.6 ± 1.9 (8)	2.8 ± 0.7 (4)
kidney	119 ± 15 (0.1)	121 ± 17 (0.1)	111 ± 34 (0.1)	132 ± 12 (0.1)	169 ± 29 (0.1)	234 ± 140 (0.1)	101 ± 30 (0.1)
muscle	2.7 ± 2.4 (3)	0.8 ± 0.2 (17)	0.6 ± 0.2 (21)	0.4 ± 0.1 (31)	1.0 ± 0.1 (12.5)	0.4 ± 0.1 (33)	0.25 ± 0.03 (44)
small int.	4.9 ± 1.9 (2)	3.8 ± 0.4 (3.5)	1.5 ± 0.3 (8)	1.5 ± 0.2 (8)	1.0 ± 0.4 (12.5)	0.25 ± 0.1 (54)	0.1 ± 0.1 (110)
large int.	1.4 ± 0.6 (6)	1.0 ± 0.2 (13.5)	0.6 ± 0.1 (21)	0.7 ± 0.6 (17)	0.6 ± 0.2 (21)	1.6 ± 1.9 (9)	0.15 ± 0.1 (73)
bladder	5.2 ± 1.7 (2)	6.1 ± 0.8 (2)	4.0 ± 2.6 (3)	3.0 ± 1.7 (4)	0.8 ± 0.3 (16)	0.2 ± 0.2 (64)	0.3 ± 0.04 (37)
PC-3 PIP	8.8 ± 4.7	13.5 ± 2.1	11.8 ± 5.6	12.4 ± 6.4	12.5 ± 4.8	13.4 ± 5.1	11.0 ± 0.2
PC-3 flu	1.8 ± 1.0	1.2 ± 0.3	0.7 ± 0.3	0.6 ± 0.05	0.3 ± 0.1	0.1 ± 0.06	0.08 ± 0.06
PIP:flu	5	11	17	21	42	134	138

^a Values are in % ID/g ± SD; ND = not determined; *n* = 4 except at 48 h where *n* = 3. int. = intestine. ^b PSMA⁺ PC-3 PIP tumor:organ ratios are in parentheses.




Figure 3. [125 I]3 SPECT-CT in PCa tumor models (4 h postinjection). Note uptake within the PSMA⁺ PIP tumor only. Uptake within kidneys is due in large measure to the specific binding of [125 I]3 to renal cortex.

Table 3 illustrates tissue uptake of [18 F]6. This radiopharmaceutical also displayed rapid, specific uptake within PSMA⁺ PIP tumors ($8.6 \pm 3.1\%$ ID/g at 30 min pi). At 1 h pi, the PSMA⁺ PC-3 PIP:PC-3 flu ratio was 21:1. As with [125 I]3, the PSMA⁺ PC-3 PIP:kidney ratio remained roughly constant (1:

Table 3. Ex Vivo Biodistribution of [18 F]6 in Tumor-Bearing Mice^{a,b}

	30 min	60 min	2 h	5 h
blood	2.5 ± 1.7 (3)	0.7 ± 0.5 (9)	0.4 ± 0.2 (9)	0.03 ± 0.00 (117)
heart	0.8 ± 0.1 (11)	0.2 ± 0.02 (35)	0.15 ± 0.05 (25)	0.03 ± 0.01 (117)
lung	1.7 ± 0.3 (5)	0.5 ± 0.1 (13)	1.0 ± 0.9 (4)	0.1 ± 0.1 (35)
liver	8.7 ± 1.8 (1)	5.8 ± 0.6 (1)	11.7 ± 7.0 (0.3)	1.0 ± 0.6 (3.5)
stomach	0.8 ± 0.1 (11)	0.25 ± 0.1 (26)	0.3 ± 0.1 (13)	0.04 ± 0.02 (88)
pancreas	0.8 ± 0.1 (11)	0.3 ± 0.1 (21)	0.15 ± 0.03 (25)	0.05 ± 0.03 (70)
spleen	12.7 ± 0.4 (0.7)	7.2 ± 1.6 (1)	4.4 ± 1.2 (1)	1.0 ± 0.6 (3.5)
kidney	72 ± 3 (0.1)	48 ± 5 (0.1)	29 ± 12 (0.1)	14 ± 9 (0.3)
muscle	2.4 ± 3.1 (4)	0.5 ± 0.7 (13)	0.2 ± 0.1 (19)	0.1 ± 0.1 (35)
small int.	1.7 ± 0.7 (5)	0.6 ± 0.2 (11)	0.3 ± 0.2 (12)	0.1 ± 0.04 (35)
large int.	1.2 ± 0.8 (7)	0.5 ± 0.1 (13)	0.2 ± 0.1 (19)	0.6 ± 0.6 (6)
bladder	6.8 ± 3.5 (1)	17 ± 21 (0.4)	11 ± 8 (0.3)	5.2 ± 8.9 (0.7)
PC-3 PIP	8.6 ± 3.1	6.4 ± 0.9	3.7 ± 1.2	3.5 ± 2.3
PC-3 flu	0.8 ± 0.3	0.3 ± 0.05	0.25 ± 0.1	0.1 ± 0.1
PIP:flu	11	21	15	35

^a Values are in % ID/g ± SD, *n* = 4, int. = intestine. ^b PSMA⁺ PC-3 PIP tumor:organ ratios are in parentheses.

10) over the length of the biodistribution. Uptake in and washout from nonspecific tissues were low and fast, respectively. Only the liver and spleen displayed uptake values that rivaled those seen in PSMA⁺ PC-3 PIP tumor, although this radioactivity cleared with time. Compared to [18 F]DCFBC,²⁴ [18 F]6 had similar PSMA⁺ PC-3 PIP tumor uptake but slower clearance from nontarget tissues, including liver, spleen, and kidney.

Compound [18 F]6 was injected intravenously into a tumor-bearing mouse for PET imaging. Figure 4 shows the averaged results of the dynamic scan from 94–120 min pi. The uptake pattern for [18 F]6 is very similar to that seen for [125 I]3: easily observed within PSMA⁺ PIP tumor, none within flu tumor, high renal uptake, and a modest degree of liver uptake. That result was expected due to similar ClogD values for [18 F]6 (−5.64 at pH 7.4) and [125 I]3. The urinary bladder was visualized at 2 h pi due to the continually accumulating presence of radioactive urine, however, as with [125 I]3, specific binding to the bladder wall was not demonstrated.

Table 4 outlines the ex vivo rodent tissue distribution results of [125 I]8. The liver, spleen, kidney, and PSMA⁺ PC-3 PIP tumor displayed high uptake at the initial, 30 min pi, time point. By 60 min pi, the kidney displayed the highest uptake while that in PSMA⁺ PC-3 PIP tumor remained steady, showing a similar value to that at 30 min. By 24 h, there was complete clearance of radioactivity from the individual, nontarget organs. The values noted in the kidney are largely due to specific binding rather than renal clearance, as for the other radiopharmaceuticals discussed above. Urinary bladder uptake represented excretion at all time points, i.e., there was no specific binding to bladder wall, while tumor uptake demonstrated a high degree of




Figure 4. [^{18}F]**6** PET coregistered to CT in PCa tumor models (~100 min postinjection). Note uptake within the PSMA⁺ PIP tumor only. Uptake within kidneys is due in large measure to the specific binding of [^{125}I]**3** to renal cortex. There is more intense tumor uptake and less liver seen with this agent than with [^{125}I]**3**.

specificity represented by the PSMA⁺ PC-3 PIP:PC-3 flu uptake ratio of 18:1 at 30 min, rising to 47:1 at 8 h. In addition, the radiopharmaceutical uptake within tumor relative to other organs increased with time due to the rapid clearance from normal organs. That was most noticeable in the clearance from the spleen, where the PSMA⁺ PC-3 PIP:spleen ratio increased from 0.5:1 at 0.5 h to 3:1 at 4 h compared to [^{125}I]**3**, where the ratios only increased from 1:10 at 0.5 h to 1:5 at 48 h.

Compound [^{125}I]**8** was injected intravenously into a SCID mouse bearing an LNCaP (PSMA⁺) tumor followed by SPECT-CT imaging. Figure 5 shows a SPECT-CT image of radiopharmaceutical uptake at 4 h pi. Tumor uptake was high, with little uptake in normal tissues. At 4 h pi, the radioactivity in the tumor appeared even more intense than that in the kidneys.

Discussion

Unlike many other cancers, PCa is particularly difficult to detect using existing molecular imaging radiotracers. There are several reasons for that, including the relatively slow growth and metabolic rate of PCa compared to other malignancies as well as the small size of the organ and proximity to the urinary bladder, into which most radiopharmaceuticals are eventually excreted. Molecular imaging may provide a way not only to detect tumor in vivo but also to provide information regarding the biology of the lesion if a mechanism-specific agent is used.

For example, [^{18}F]FDHT can be used to study the androgen receptor status of tumors.¹⁴ Likewise, the PSMA-based agents described here can report on the presence of this marker, which is increasingly recognized as an important prognostic determinant in PCa.⁴² It is also the target for a variety of new PCa therapies.⁴³

Among the three compounds discussed here, namely [^{125}I]**3**, [^{18}F]**6**, and [^{125}I]**8**, [^{125}I]**3**, and [^{125}I]**8** are designed for SPECT imaging, if ^{123}I is substituted for the ^{125}I used in this experimental study, while [^{18}F]**6** is designed for PET. In principle, all three compounds can be used for PET if the two radioiodinated compounds are labeled with ^{124}I . The two radioiodinated compounds were prepared in high yield and specific radioactivity, while [^{18}F]**6** was prepared in high radiochemical yield, but the specific activity was relatively low, due to the low amount of starting [^{18}F]F[−] (40 mCi) used in the manual synthesis here described. The specific radioactivity of the starting [^{18}F]F[−] can be improved by using higher levels of [^{18}F]F[−] and a remote synthesis. In each case, the radiosynthesis was straightforward, as [^{125}I]**3** and [^{18}F]**6** could be synthesized by coupling the intermediate Lys-C(O)-Glu with the corresponding *N*-hydroxysuccinimide benzoate, while a similar approach was used for [^{125}I]**8**, merely replacing the benzoate with a pyridinecarboxylate moiety. The synthesis of both the halobenzoate and pyridinecarboxylate radionuclide-bearing precursors have been published,^{44,45,28,30} while the Lys-C(O)-Glu urea precursor has been used by us previously to develop SPECT agents.²⁵ The relative ease of synthesis of compounds of this class suggests that they will be amenable for use at a wide variety of imaging centers.

Not surprisingly, **3**, **6**, and **8** assume similar conformations within the PSMA active site. The radionuclide-bearing moiety resides within the arginine patch region of the S1 binding site in each case, however, that of **8** is not as deep within the pocket (Figure 2a). Compound **3** has been cocrystallized with PSMA (in press), and the aromatic phenyl ring for that compound shows productive cation- π stacking interactions with guanidine functions of Arg 463 and Arg 534 of the enzyme, whereas the pyridine moiety of **8** forms a less productive cation- π interaction. However, unlike **3** or **6**, **8** was found to be able to interact with Asp 465 (via the pyridine nitrogen) and a water molecule (via the carbonyl group of 5-iodonicotinamido moiety) in the S1' subpocket (see Supporting Information, Figure 5). Those additional interactions likely offset the less productive cation- π interaction geometry of **8**, providing a high-affinity interaction and an imaging agent that gives clear delineation of tumor (Figure 5). While **6** adopts a very similar conformation within the active site to **3**, it binds with lower affinity, likely due to additional interactions of the iodine within the positively charged arginine patch for **3**. In all, the affinities of **3**, **6**, and **8** (Table 1) track with predictions based on molecular modeling.

Regarding ex vivo biodistribution, [^{125}I]**3** demonstrated only about twice the tumor uptake at 1 h pi as [^{18}F]**6**, while its affinity is about 25 times higher. The target to nontarget (PSMA⁺ PC-3 PIP:PC-3 flu) ratios for [^{18}F]**6**, however were higher than that for [^{125}I]**3** at 0.5–1 h pi, reflecting lower nonspecific binding, however the two compounds are equivalent by 2 h. Target to nontarget ratios rise to approximately 140 at 48 h pi for [^{125}I]**3** and to 35 at 5 h pi for [^{18}F]**6**. Compound [^{125}I]**8** differs from [^{125}I]**3** in that the aromatic ring is a pyridine and the iodine is substituted at the 3-position. At 1 h pi [^{125}I]**8** demonstrated a similarly high tumor uptake ($12.1 \pm 4.9\%$ ID/g) compared to [^{125}I]**3** but had a much higher target to nontarget tissue ratio at that time (20), which rose to 47 at 8 h pi. Compound [^{125}I]**3** took 12 h to reach that ratio. Interestingly, the affinity of [^{125}I]**8**

Table 4. Ex Vivo Biodistribution of [125 I]**8** in Tumor-Bearing Mice^{a,b}

organ	30 min	60 min	4 h	8 h	24 h
blood	2.5 ± 1.4 (6)	1.1 ± 0.5 (11)	0.25 ± 0.2 (17)	0.06 ± 0.01 (23)	0.00 ± 0.00
heart	0.9 ± 0.2 (16)	0.4 ± 0.3 (30)	0.06 ± 0.02 (20)	0.02 ± 0.01 (70)	0.00 ± 0.00
lung	2.7 ± 3.2 (5)	2.3 ± 1.0 (5)	0.3 ± 0.1 (14)	0.1 ± 0.05 (12)	0.01 ± 0.00 (9)
liver	8.2 ± 1.2 (2)	9.7 ± 1.2 (1)	4.8 ± 0.9 (1)	1.6 ± 0.4 (1)	0.04 ± 0.03 (2)
stomach	0.8 ± 0.3 (18)	0.5 ± 0.3 (23)	0.1 ± 0.05 (42)	0.06 ± 0.02 (23)	0.01 ± 0.01 (9)
pancreas	0.9 ± 0.2 (15)	0.8 ± 0.3 (16)	0.3 ± 0.3 (14)	0.03 ± 0.00 (47)	0.00 ± 0.00
spleen	26 ± 12 (0.5)	13.0 ± 6.8 (1)	1.25 ± 0.4 (3)	0.5 ± 0.2 (3)	0.03 ± 0.02 (3)
fat	3.5 ± 0.2 (4)	1.4 ± 0.5 (8)	0.04 ± 0.1 (105)	0.2 ± 0.2 (7)	0.00 ± 0.01
kidney	160 ± 27 (0.1)	205 ± 46 (0.06)	71 ± 27 (0.06)	24 ± 10 (0.06)	0.97 ± 0.94 (0.1)
muscle	1.9 ± 2.4 (7)	0.9 ± 0.7 (13)	0.2 ± 0.3 (21)	0.1 ± 0.1 (14)	0.00 ± 0.00
small int.	0.8 ± 0.2 (18)	1.1 ± 1.3 (11)	0.2 ± 0.05 (21)	0.1 ± 0.02 (14)	0.01 ± 0.01 (9)
large int.	0.9 ± 0.4 (16)	0.6 ± 0.3 (21)	0.2 ± 0.1 (21)	0.1 ± 0.1 (14)	0.00 ± 0.00
bladder	1.9 ± 0.4 (8)	4.8 ± 4.9 (2.5)	7.0 ± 3.6 (0.6)	2.8 ± 2.1 (0.5)	0.05 ± 0.01 (2)
PC-3 PIP	14.2 ± 9.5	12.1 ± 4.9	4.2 ± 1.5	1.4 ± 0.4	0.09 ± 0.04
PC-3 flu	0.8 ± 0.1	0.6 ± 0.25	0.1 ± 0.02	0.03 ± 0.01	0.00 ± 0.00
PIP:flu	18	20	42	47	

^a Values are in % ID/g ± SD; *n* = 4; int. = intestine. ^b PSMA⁺ PC-3 PIP tumor:organ ratios are in parentheses.




Figure 5. [125 I]**8** SPECT-CT in PSMA⁺ LNCaP tumors (4 h postinjection). Note intense uptake within tumor. A similar result was obtained for PSMA⁺ PIP but not PSMA⁻ flu tumors (data not shown). There is less renal and liver uptake with this agent than the halobenzoyletated analogues, [125 I]**3** and [18 F]**6**, respectively.

is the lowest among the three compounds tested (Table 1), however, compared with [125 I]**3**, it provided a higher target to nontarget ratio at 1 h pi, equivalent to that of [125 I]**3** at 2–5 h pi. As demonstrated in our previous work with 99m Tc-labeled

compounds of this series, we again show that there is not a clear relationship between affinity and in vivo tumor uptake selectivity. Notably, the affinities of these compounds are quite high (Table 1) and the tumors are clearly delineated (Figures 3, 5).

On the basis of the in vivo imaging studies, [125 I]**3** and [125 I]**8** have appropriate pharmacokinetics and imaging characteristics for imaging of PSMA⁺ prostate cancer with SPECT when radiolabeled with 125 I, while [18 F]**6** and [124 I]**3** would be useful for PET. All compounds demonstrate high target to nontarget tissue ratios relatively soon after injection, making any of them convenient for clinical use. The syntheses are also adaptable to an automated format. Although our previous 18 F-labeled inhibitor, [18 F]DCFBC,²⁴ produced higher PSMA⁺ PC-3 PIP:organ ratios than [18 F]**6**, [18 F]**6** can be prepared in higher radiochemical yield. Additionally, automated syntheses of [18 F]SFB, the precursor for [18 F]**6**, have been reported, suggesting that the radiosynthesis of [18 F]**6** may be easier to automate.^{46,47} Radiation dosimetry and toxicity studies of this latest series of compounds are currently under way.

Experimental Section

General Procedures. All reagents and solvents were purchased from either Sigma-Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). The tosylate salt of **1** was prepared according to a reported procedure.²⁵ 1 H NMR spectra were obtained on a Varian Mercury 400 MHz or a Bruker Avance 400 MHz spectrometer. ESI mass spectra were obtained on an API 150EX or a Bruker Esquire 3000 plus system. High-resolution mass spectra (HRMS) were performed on a JEOL JMS-AX505HA mass spectrometer in the Mass Spectrometry Facility at the University of Notre Dame. HPLC purification of nonradioactive compounds was performed on a Waters 625 LC system with a Waters 490E multiwavelength UV/vis detector (Milford, MA).

[125 I]NaI was purchased from MP Biomedicals (Costa Mesa, CA). [18 F]Fluoride was produced by 18 MeV proton bombardment of a high pressure [18 O]H₂O target using a General Electric PETtrace biomedical cyclotron (Milwaukee, WI). Solid-phase extraction cartridges (C₁₈ plus, Sep-Pak) were purchased from Waters Associates. Reverse phase radio-HPLC purification of [125 I]**3** and [125 I]**8** were performed using a Waters 510 pump, Waters 490E variable wavelength UV/vis detector at 254 nm, and a Bioscan Flow Count PMT radioactivity detector (Washington, DC). Reverse phase radio-HPLC purification of [18 F]**6** was performed using a Varian Prostar System with a Bioscan Flow Count PMT radioactivity detector. Radioactivity was measured in a Capintec CRC-10R dose calibrator (Ramsey, NJ). The specific radioactivity was calculated as the radioactivity eluting at the retention time of product during

the preparative HPLC purification divided by the mass corresponding to the area under the curve of the UV absorption.

2-[3-[5-(4-Iodo-benzoylamino)-1-(4-methoxy-benzoyloxycarbonyl)-pentyl]-ureido]-pentanedioic Acid Bis-(4-methoxy-benzyl) ester (2). To a solution of **1** (0.126 g, 0.148 mmol) in CH_2Cl_2 (4 mL) was added triethylamine (0.1 mL, 0.712 mmol), followed by *N*-hydroxysuccinimidyl-4-iodobenzoate⁴⁸ (0.073 g, 0.212 mmol). After stirring for 2 h at room temperature, the solvent was evaporated on a rotary evaporator. The crude material was purified on a silica column using methanol/methylene chloride (5:95) to afford 0.127 g (94%) of **2**. ¹H NMR (400 MHz, CDCl_3) δ 7.69 (d, *J* = 8.8 Hz, 2H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.17–7.26 (m, 6H), 6.77–6.86 (m, 7H), 5.37–5.46 (m, 2H), 4.93–5.09 (m, 6H), 4.32–4.40 (m, 2H), 3.76–3.77 (m, 9H), 3.30–3.33 (m, 2H), 2.30–2.36 (m, 2H), 2.07–2.12 (m, 1H), 1.84–1.92 (m, 1H), 1.70–1.79 (m, 1H), 1.49–1.57 (m, 3H), 1.25–1.33 (m, 2H). ESI-Mass calcd for $\text{C}_{43}\text{H}_{48}\text{IN}_3\text{O}_{11}\text{Na}$ [*M* + *Na*]⁺ 932.2, found 932.7.

2-[3-[1-Carboxy-5-(4-iodo-benzoylamino)-pentyl]-ureido]-pentanedioic Acid (3). A solution of 3% anisole in TFA (15 mL) was added to **2** (0.117 g, 0.129 mmol) at 0 °C. The mixture was stirred at room temperature for 30 min and then concentrated on a rotary evaporator. The crude material was purified by HPLC (Econosil C18 10 μ , 250 mm $\times$ 10 mm, $\text{H}_2\text{O}/\text{CH}_3\text{CN}/\text{TFA}$ (70/30/0.1), 4 mL/min, **3** eluting at 11 min) to afford 0.040 g (57%) of **3**. ¹H NMR (400 MHz, $\text{D}_2\text{O}:\text{CD}_3\text{CN}$ = 1:1 (v/v)) δ 7.79 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 4.08–4.16 (m, 2H), 3.26 (m, 2H), 2.35 (m, 2H), 2.00–2.03 (m, 1H), 1.72–1.84 (m, 2H), 1.52–1.62 (m, 3H), 1.34–1.36 (m, 2H). ESI-Mass calcd for $\text{C}_{19}\text{H}_{24}\text{IN}_3\text{O}_8\text{Na}$ [*M* + *Na*]⁺ 572.1, found 572.0. FAB-HRMS calcd for $\text{C}_{19}\text{H}_{25}\text{IN}_3\text{O}_8$ [*M* + *H*]⁺ 550.0686, found 550.0648.

2-[3-[1-(4-Methoxy-benzoyloxycarbonyl)-5-(4-tributylstannyl-benzoylamino)-pentyl]-ureido]-pentanedioic Acid Bis-(4-methoxy-benzyl) Ester (4). To a solution of **1** (0.120 g, 0.148 mmol) in CH_2Cl_2 (6 mL) was added triethylamine (0.1 mL, 0.712 mmol), followed by *N*-hydroxysuccinimidyl-4-tributylstannylbenzoate⁴⁸ (0.075 g, 0.147 mmol). After stirring for 2 h at room temperature, the reaction mixture was condensed on a rotary evaporator. The crude material was purified on a silica column using methanol/methylene chloride (5:95) to afford 0.130 g (86%) of **4**. ¹H NMR (400 MHz, CDCl_3) δ 7.68 (d, *J* = 8.4 Hz, 2H), 7.49 (d, *J* = 7.6 Hz, 2H), 7.18–7.24 (m, 6H), 6.80–6.85 (m, 6H), 6.47 (m, 1H), 5.44–5.47 (m, 2H), 4.95–5.09 (m, 6H), 4.41–4.45 (m, 2H), 3.76–3.77 (m, 9H), 3.32–3.38 (m, 2H), 2.35–2.37 (m, 2H), 2.08–2.16 (m, 1H), 1.90–1.94 (m, 1H), 1.70–1.79 (m, 1H), 1.45–1.64 (m, 9H), 1.24–1.30 (m, 8H), 1.01–1.06 (m, 6H), 0.85–0.87 (m, 9H). ESI-Mass calcd for $\text{C}_{55}\text{H}_{75}\text{N}_3\text{O}_{11}\text{SnNa}$ [*M* + *Na*]⁺ 1096.4, found 1096.7.

2-[3-[5-(4-Fluoro-benzoylamino)-1-(4-methoxy-benzoyloxycarbonyl)-pentyl]-ureido]-pentanedioic Acid Bis-(4-methoxy-benzyl) Ester (5). To a solution of **1** (0.140 g, 0.164 mmol) in CH_2Cl_2 (4 mL) was added triethylamine (0.1 mL, 0.712 mmol), followed by *N*-hydroxysuccinimidyl-4-fluorobenzoate⁴⁹ (0.043 g, 0.181 mmol). After stirring for 2 h at room temperature, the solvent was evaporated on a rotary evaporator. The crude material was purified by on a silica column using methanol/methylene chloride (5:95) to afford 0.120 g (91%) of **5**. ¹H NMR (400 MHz, CDCl_3) δ 7.78 (m, 2H), 7.16–7.24 (m, 6H), 7.01 (m, 2H), 6.80–6.85 (m, 7H), 5.51–5.64 (m, 2H), 4.93–5.09 (m, 6H), 4.34–4.40 (m, 2H), 3.75–3.77 (m, 9H), 3.28–3.34 (m, 2H), 2.26–2.38 (m, 2H), 2.04–2.15 (m, 1H), 1.82–1.91 (m, 1H), 1.68–1.74 (m, 1H), 1.44–1.57 (m, 3H), 1.25–1.33 (m, 2H). ESI-Mass calcd for $\text{C}_{43}\text{H}_{48}\text{FN}_3\text{O}_{11}\text{Na}$ [*M* + *Na*]⁺ 824.3, found 824.7.

2-[3-[1-Carboxy-5-(4-fluoro-benzoylamino)-pentyl]-ureido]-pentanedioic Acid (6). A solution of 3% anisole in TFA (15 mL) was added to **5** (0.081 g, 0.1 mmol) at 0 °C. The mixture was stirred at room temperature for 20 min then concentrated on a rotary evaporator. The crude material was purified by HPLC (Econosil C18 10 μ , 250 mm $\times$ 10 mm, $\text{H}_2\text{O}/\text{CH}_3\text{CN}/\text{TFA}$ (75/25/0.1), 4 mL/min, **6** eluting at 9 min) to afford 0.035 g (79%) of **6**. ¹H NMR (400 MHz, D_2O) δ 7.66–7.69 (m, 2H), 7.11–7.16 (m, 2H), 4.12–4.19 (m, 2H), 3.28–3.31 (m, 2H), 2.39–2.43 (m, 2H),

2.07–2.09 (m, 1H), 1.79–1.90 (m, 2H), 1.55–1.69 (m, 3H), 1.39–1.40 (m, 2H). ESI-Mass calcd for $\text{C}_{19}\text{H}_{24}\text{FN}_3\text{O}_8\text{Na}$ [*M* + *Na*]⁺ 464.1, found 464.4. FAB-HRMS calcd for $\text{C}_{19}\text{H}_{25}\text{FN}_3\text{O}_8$ [*M* + *H*]⁺ 442.1626, found 442.1646.

2-(3-[1-(4-Methoxy-benzoyloxycarbonyl)-5-[(5-tributylstannyl-pyridine-3-carbonyl)-aminol]-pentyl]-ureido)-pentanedioic Acid Bis-(4-methoxy-benzyl) Ester (7). To a solution of **1** (0.120 g, 0.148 mmol) in CH_2Cl_2 (2 mL) was added triethylamine (0.1 mL, 0.712 mmol), followed by *N*-hydroxysuccinimidyl-5-(tri-*n*-butylstannyl)-3-pyridinecarboxylate^{50,51} (0.075 g, 0.147 mmol). After stirring for 30 min at room temperature, the crude material was purified on a silica column using methanol/methylene chloride (5:95) to afford 0.115 g (76%) of **7**. ¹H NMR (400 MHz, CDCl_3) δ 8.85 (s, 1H), 8.65 (s, 1H), 8.19 (s, 1H), 7.19–7.24 (m, 6H), 6.81–6.85 (m, 6H), 6.65 (m, 1H), 5.32–5.35 (m, 1H), 5.22–5.25 (m, 1H), 4.96–5.10 (m, 6H), 4.40–4.47 (m, 2H), 3.70–3.77 (m, 9H), 3.34 (m, 2H), 2.35–2.39 (m, 2H), 2.10–2.15 (m, 1H), 1.90–1.94 (m, 1H), 1.72–1.79 (m, 1H), 1.46–1.59 (m, 9H), 1.27–1.36 (m, 8H), 1.02–1.25 (m, 6H), 0.84–0.87 (m, 9H). ESI-Mass calcd for $\text{C}_{54}\text{H}_{75}\text{N}_4\text{O}_{11}\text{Sn}$ [*M* + *H*]⁺ 1075.4, found 1075.5.

2-(3-[1-Carboxy-5-[(5-iodo-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pentanedioic Acid (8). To a solution of **7** (0.025 g, 0.023 mmol) in 2 mL of methanol was added 0.020 mL of acetic acid and sodium iodide (0.017 g, 0.113 mmol), followed by *N*-chlorosuccinimide (0.025 g, 0.187 mmol). After 20 min at room temperature, the solvent was removed under a stream of nitrogen. A solution of TFA in CH_2Cl_2 (1:1, 2 mL) was then added to the residue. After 1 h at room temperature, **8** (0.008 g, 62%) was isolated by HPLC (Econosphere C18 10 μ , 250 mm $\times$ 10 mm, $\text{H}_2\text{O}/\text{CH}_3\text{CN}/\text{TFA}$ (85/15/0.1), 4 mL/min, product peak eluting at 10 min). ¹H NMR (400 MHz, D_2O) δ 9.00–9.15 (m, 3H), 4.18–4.24 (m, 2H), 3.40–3.41 (m, 2H), 2.45–2.49 (m, 2H), 2.12–2.13 (m, 1H), 1.85–1.97 (m, 2H), 1.64–1.73 (m, 3H), 1.44 (m, 2H). ESI-Mass calcd for $\text{C}_{18}\text{H}_{24}\text{IN}_4\text{O}_8$ [*M* + *H*]⁺ 551.1, found 551.0. FAB-HRMS calcd for $\text{C}_{18}\text{H}_{24}\text{IN}_4\text{O}_8$ [*M* + *H*]⁺ 551.0639, found 551.0607.

Radiochemistry. 2-[3-[1-Carboxy-5-(4-[¹²⁵I]iodo-benzoylamino)-pentyl]-ureido]-pentanedioic Acid ([¹²⁵I]3**).** To a solution of **4** (1 mg, 0.932 μ mol) in 0.1 mL of methanol was added 0.001 mL of acetic acid and 1–4 μ L (1–4 mCi) (37–148 MBq) [¹²⁵I]NaI solution, followed by *N*-chlorosuccinimide (0.25 mg, 0.187 μ mol) in 0.025 mL of methanol. After stirring at room temperature for 20 min, the solvent was removed under a stream of N_2 . A solution of 3% anisole in TFA (0.1 mL) was then added to the residue. After 5 min at room temperature, solvent was removed under a stream of N_2 and then [¹²⁵I]**3** was isolated by radio-HPLC (Econosil C18 10 $\mu</$

2-(3-[1-Carboxy-5-[(5-[¹²⁵I]iodo-pyridine-3-carbonyl)-amino]-pentyl]-ureido)-pentanedioic Acid ([¹²⁵I]8). To a solution of 7 (0.1 mg, 0.093 μ mol) in 0.1 mL of methanol was added 0.001 mL of acetic acid, 3 μ L (2.7 mCi) (100 MBq) of [¹²⁵I]NaI, followed by *N*-chlorosuccinimide (0.03 mg, 0.225 μ mol) in 0.010 mL of methanol. After 20 min at room temperature, the solvent was removed under a stream of nitrogen. A solution of 3% anisole in TFA (0.1 mL) was then added to the residue. After 5 min at room temperature, solvent was removed under a stream of N₂ and then [¹²⁵I]8 was isolated by HPLC (Econosil C18 10 μ , 250 mm $\times$ 4.6 mm, H₂O/CH₃CN/TFA [85/15/0.1], 1 mL/min), neutralized, concentrated, and filtered as above. The radiochemical yield ranged from 59–75%, and the specific activity was greater than 2000 Ci/nmol (74.0 GBq/ μ mol).

NAALADase Assay. NAAG hydrolysis was performed essentially as described previously.^{31,52} Briefly, LNCaP cell extracts were prepared by sonication in NAALADase buffer (50 mM Tris [pH 7.4] and 0.5% Triton X-100). Cell lysates were incubated with or without inhibitor at 37 °C for 10 min. Following the incubation, the radiolabeled substrate *N*-acetyl-L-aspartyl-L-(3,4-³H)glutamate (NEN Life Science Products, Boston, MA) was added to a final concentration of 30 nM at 37 °C for 10–15 min. The reaction was stopped by the addition of an equal volume of ice-cold 100 mM sodium phosphate and 2 mM EDTA. Products were partitioned by AG 1-X8 formate resin (Bio-Rad Laboratories, Hercules, CA) anion exchange chromatography, eluted with 1 M sodium formate, and quantified by liquid scintillation counting. Inhibition curves were determined using semilog plots, and IC₅₀ values were determined at the concentration at which enzyme activity was inhibited by 50%. Assays were performed in triplicate, with the entire inhibition study being repeated at least once to confirm affinity and mode of inhibition. Data were collected during the linear phase of hydrolysis (i.e., < 20% cleavage of total substrate). Enzyme inhibitory constants (*K_i* values) were generated using the Cheng–Prusoff conversion.⁵³ Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, CA). PSMA activity was also determined using a fluorescence-based assay according to a previously reported procedure.³² Briefly, lysates of LNCaP cell extracts were incubated with inhibitor in the presence of 4 μ M NAAG. The amount of reduced glutamate was measured by incubating with a working solution of the Amplex Red glutamic acid kit (Molecular Probes Inc., Eugene, OR). The fluorescence was measured with a VICTOR3V multilabel plate reader (Perkin-Elmer Inc., Waltham, MA) with excitation at 490 nm and emission at 642 nm.

Cell Lines and Mouse Models. PC-3 PIP (PSMA⁺) and PC-3 flu (PSMA⁻) cell lines were obtained from Dr. Warren Heston (Cleveland Clinic) and were maintained as previously described.²⁵ LNCaP cells were obtained from Dr. Ron Rodriguez (JHU) and were maintained as described.²⁵ All cells were grown to 80–90% confluence before trypsinization and formulation in Hank's Balanced Salt Solution (HBSS, Sigma, St. Louis, MO) for implantation into mice.

All animal studies were undertaken in full compliance with institutional guidelines related to the conduct of animal experiments. Male SCID mice (Charles River Laboratories, Wilmington, MA) were implanted subcutaneously with 1–5 $\times$ 10⁶ for PC-3s and 5 $\times$ 10⁶ for LNCaPs forward of each shoulder. PSMA⁺ PC-3 PIP cells were implanted behind the left shoulder, and PC-3 flu cells were implanted behind the right shoulder. Mice were imaged or used in biodistribution assays when the tumor xenografts reached 3–5 mm in diameter.

Ex Vivo Biodistribution and Imaging. Compound [¹²⁵I]3. Xenograft-bearing SCID mice were injected via the tail vein with 2 μ Ci (74 Bq) of [¹²⁵I]3. Four mice each were sacrificed by cervical dislocation at 30, 60, 120, 300 min, 12, 24, and 48 h pi. The heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, and PSMA⁺ PC-3 PIP and flu tumors were quickly removed. A 0.1 mL sample of blood was also collected. The organs were weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Com-

pugamma CS, Pharmacia/LKB Nuclear, Inc., Gaithersburg, MD). The percent-injected dose per gram of tissue (% ID/g) was calculated by comparison with samples of a standard dilution of the initial dose. All measurements were corrected for decay.

A single SCID mouse implanted with both a PSMA⁺ PC-3 PIP and a PC-3 flu xenograft was injected intravenously with 1 mCi (37 MBq) of [¹²⁵I]3 in PBS. At 4 h pi, the mouse was anesthetized with isoflurane and maintained under 1% isoflurane in oxygen. The mouse was positioned on the X-SPECT (Gamma Medica, Northridge, CA) gantry and was scanned using two low energy, high-resolution pinhole collimators (Gamma Medica) rotating through 360° in 6° increments for 45 s per increment. All gamma images were reconstructed using LumaGEM software (Gamma Medica, Northridge, CA). Immediately following SPECT acquisition, the mice were then scanned by CT (X-SPECT) over a 4.6 cm field-of-view using a 600 μ A, 50 kV beam. The SPECT and CT data were then coregistered using the supplier's software (Gamma Medica) and displayed using AMIDE (<http://amide.sourceforge.net/>). Data were reconstructed using the ordered subsets-expectation maximization (OS-EM) algorithm.

Compound [¹⁸F]6. Ex vivo biodistribution proceeded as for [¹²⁵I]3 with the following exceptions: Mice were injected with 100 μ Ci (3.7 MBq) of [¹⁸F]6 and uptake times were 30, 60, 120, and 300 min pi. In vivo PET-CT: A SCID mouse bearing subcutaneous PSMA⁺ PC-3 PIP and PC-3 flu xenografts was anesthetized using 3% isoflurane in oxygen for induction and 1.5% isoflurane in oxygen at 0.8 L/min flow for maintenance. The animal was placed in the prone position on the gantry of a GE eXplore Vista small animal PET scanner (GE Healthcare, Milwaukee, WI). The mouse was injected intravenously with 200 μ Ci (7.4 MBq) of [¹⁸F]6, followed by image acquisition using the following protocol: The images were acquired as a pseudodynamic scan, i.e., a sequence of successive whole-body images were acquired in three bed positions for a total of 120 min. The dwell time at each position was 5 min, such that a given bed position (or mouse organ) was revisited every 15 min. An energy window of 250–700 keV was used. Images were reconstructed using the FORE/2D-OSEM method (2 iterations, 16 subsets) and included corrections for radioactive decay, scanner dead time, and scattered radiation.

Compound [¹²⁵I]8. PSMA⁺ PC-3 PIP and PC-3 flu xenograft-bearing SCID mice were injected via the tail vein with 2 μ Ci (74 KBq) of [¹²⁵I]8. Four mice each were sacrificed by cervical dislocation at 30, 60, 240 min, 8 and 24 h pi. The heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, and PSMA⁺ PC-3 PIP and flu tumors were quickly removed. A 0.1 mL sample of blood was also collected. All organs were weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Compugamma CS, Pharmacia/LKB Nuclear, Inc., Gaithersburg, MD). The %ID/g was calculated by comparison with samples of a standard dilution of the initial dose. All measurements were corrected for decay.

A single SCID mouse implanted with a LNCaP xenograft was injected intravenously with 1 mCi (37 MBq) of [¹²⁵I]8 in PBS. At 4 h pi, the mouse was anesthetized with isoflurane and maintained under 1% isoflurane in oxygen. The mouse was positioned on the X-SPECT (Gamma Medica, Northridge, CA) gantry and was scanned using two low energy, high-resolution pinhole collimators (Gamma Medica) rotating through 360° in 6° increments for 45 s per increment. All gamma images were reconstructed using LumaGEM software (Gamma Medica, Northridge, CA). Immediately following SPECT acquisition, the mice were then scanned by CT (X-SPECT) over a 4.6 cm field-of-view using a 600 μ A, 50 kV beam. The SPECT and CT data were then coregistered using the supplier's software (Gamma Medica) and displayed using AMIDE (<http://amide.sourceforge.net/>). Data were reconstructed using the OS-EM algorithm.

Acknowledgment. This work was supported by NIH CA92871, CA111411, EB005324, and the AdMeTech Foundation. We thank Gilbert Green for technical assistance. We

also thank Dr. Warren Heston for providing the PC-3 PIP and flu cells, and Dr. Alan Kozikowski for helpful discussions.

Supporting Information Available: Methods of molecular modeling, protein preparation, ligand preparation, and docking studies with CDOCKER are described in detail. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References

- Jemal, A.; Murray, T.; Samuels, A.; Ghafoor, A.; Ward, E.; Thun, M. J. Cancer statistics, 2003. *CA Cancer J. Clin.* **2003**, *53*, 5–26.
- Mueller-Lisse, U. G.; Scherr, M. K. Proton MR spectroscopy of the prostate. *Eur. J. Radiol.* **2007**, *63*, 351–360.
- Geus-Oei, L. F.; Oyen, W. J. Predictive and prognostic value of FDG-PET. *Cancer Imaging* **2008**, *8*, 70–80.
- Wester, H. J. Nuclear imaging probes: from bench to bedside. *Clin. Cancer Res.* **2007**, *13*, 3470–3481.
- Scher, B.; Seitz, M.; Albinger, W.; Tiling, R.; Scherr, M.; Becker, H. C.; Souvatzoglou, M.; Gildehaus, F. J.; Wester, H. J.; Dresel, S. Value of ¹¹C-choline PET and PET/CT in patients with suspected prostate cancer. *Eur. J. Nucl. Med. Mol. Imaging* **2007**, *34*, 45–53.
- Rinnab, L.; Mottaghy, F. M.; Blumstein, N. M.; Reske, S. N.; Hautmann, R. E.; Hohl, K.; Moller, P.; Wiegand, T.; Kuefer, R.; Gschwend, J. E. Evaluation of [¹¹C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. *BJU Int.* **2007**, *100*, 786–793.
- Reske, S. N.; Blumstein, N. M.; Neumaier, B.; Gottfried, H. W.; Finsterbusch, F.; Kocot, D.; Moller, P.; Glatting, G.; Perner, S. Imaging prostate cancer with ¹¹C-choline PET/CT. *J. Nucl. Med.* **2006**, *47*, 1249–54.
- Zophel, K.; Kotzerke, J. Is ¹¹C-choline the most appropriate tracer for prostate cancer? Against. *Eur. J. Nucl. Med. Mol. Imaging* **2004**, *31*, 756–759.
- Vees, H.; Buchegger, F.; Albrecht, S.; Khan, H.; Husarik, D.; Zaidi, H.; Soloviev, D.; Hany, T. F.; Miralbell, R. ¹⁸F-choline and/or ¹¹C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. *BJU Int.* **2007**, *99*, 1415–1420.
- Ponde, D. E.; Dence, C. S.; Oyama, N.; Kim, J.; Tai, Y. C.; Laforest, R.; Siegel, B. A.; Welch, M. J. ¹⁸F-fluoroacetate: a potential acetate analog for prostate tumor imaging—in vivo evaluation of ¹⁸F-fluoroacetate versus ¹¹C-acetate. *J. Nucl. Med.* **2007**, *48*, 420–428.
- Schuster, D. M.; Votaw, J. R.; Nieh, P. T.; Yu, W.; Nye, J. A.; Master, V.; Bowman, F. D.; Issa, M. M.; Goodman, M. M. Initial experience with the radiotracer anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. *J. Nucl. Med.* **2007**, *48*, 56–63.
- Oka, S.; Hattori, R.; Kurosaki, F.; Toyama, M.; Williams, L. A.; Yu, W.; Votaw, J. R.; Yoshida, Y.; Goodman, M. M.; Ito, O. A preliminary study of anti-1-amino-3-¹⁸F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. *J. Nucl. Med.* **2007**, *48*, 46–55.
- Tehrani, O. S.; Muzik, O.; Heilbrun, L. K.; Douglas, K. A.; Lawhorn-Crews, J. M.; Sun, H.; Mangner, T. J.; Shields, A. F. Tumor imaging using 1-(2'-deoxy-2'-¹⁸F-fluoro-beta-D-arabinofuranosyl)thymine and PET. *J. Nucl. Med.* **2007**, *48*, 1436–41.
- Larson, S. M.; Morris, M.; Gunther, I.; Beattie, B.; Humm, J. L.; Akhurst, T. A.; Finn, R. D.; Erdi, Y.; Pentlow, K.; Dyke, J.; Squire, O.; Bornmann, W.; McCarthy, T.; Welch, M.; Scher, H. Tumor localization of 16beta-¹⁸F-fluoro-5alpha-dihydrotestosterone versus ¹⁸F-FDG in patients with progressive, metastatic prostate cancer. *J. Nucl. Med.* **2004**, *45*, 366–73.
- Chang, S. S.; Reuter, V. E.; Heston, W. D.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. *Cancer Res.* **1999**, *59*, 3192–8.
- Zhou, J.; Neale, J. H.; Pomper, M. G.; Kozikowski, A. P. NAAG peptidase inhibitors and their potential for diagnosis and therapy. *Nat. Rev. Drug Discovery* **2005**, *4*, 1015–1026.
- Chang, S. S. Overview of prostate-specific membrane antigen. *Rev. Urol.* **2004**, *6* Suppl. 10, S138–S18.
- Manyak, M. J. Indium-111 capromab pendetide in the management of recurrent prostate cancer. *Expert Rev. Anticancer Ther.* **2008**, *8*, 175–181.
- Lange, P. H. PROSTASCINT scan for staging prostate cancer. *Urology* **2001**, *57*, 402–406.
- Haseman, M. K.; Rosenthal, S. A.; Polascik, T. J. Capromab Pendetide imaging of prostate cancer. *Cancer Biother. Radiopharm.* **2000**, *15*, 131–140.
- Rosenthal, S. A.; Haseman, M. K.; Polascik, T. J. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. *Tech. Urol.* **2001**, *7*, 27–37.
- Pomper, M. G.; Musachio, J. L.; Zhang, J.; Scheffel, U.; Zhou, Y.; Hilton, J.; Maini, A.; Dannals, R. F.; Wong, D. F.; Kozikowski, A. P. ¹¹C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). *Mol. Imaging* **2002**, *1*, 96–101.
- Foss, C. A.; Mease, R. C.; Fan, H.; Wang, Y.; Ravert, H. T.; Dannals, R. F.; Olszewski, R.; Heston, W. D.; Kozikowski, A. P.; Pomper, M. G. Radiolabeled Small Molecule Ligands for Prostate-Specific Membrane Antigen: In Vivo Imaging in Experimental Models of Prostate Cancer. *Clin. Cancer Res.* **2005**, *11*, 4022–4028.
- Mease, R. C.; Dusich, C. L.; Foss, C. A.; Ravert, H. T.; Dannals, R. F.; Seidel, J.; Prideaux, A.; Fox, J. J.; Sgouros, G.; Kozikowski, A. P.; Pomper, M. G. *N*-[¹⁸F]-1,3-Dicarboxypropyl[Carbamoyl]-4-[¹⁸F]Fluorobenzyl-L-Cysteine, [¹⁸F]DCFCB: A New Imaging Probe for Prostate Cancer. *Clin. Cancer Res.* **2008**, *14*, 3036–3043.
- Banerjee, S. R.; Foss, C. A.; Mease, R. C.; Fox, J.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of ^{99m}Tc/Re labeled PSMA inhibitors. *J. Med. Chem.* **2008**, *51*, 4504–4517.
- Wilbur, D. S. Radiohalogenation of proteins: an overview of radio-nuclides, labeling methods, and reagents for conjugate labeling. *Bioconjugate Chem.* **1992**, *3*, 433–470.
- Khawli, L. A.; Kassis, A. I. Synthesis of ¹²⁵I labeled *N*-succinimidyl *p*-iodobenzoate for use in radiolabeling antibodies. *Int. J. Rad. Appl. Instrum., Part B* **1989**, *16*, 727–733.
- Vaidyanathan, G.; Zalutsky, M. R. Labeling proteins with fluorine-18 using *N*-succinimidyl-4-[¹⁸F]fluorobenzoate. *Int. J. Rad. Appl. Instrum., Part B* **1992**, *19*, 275–281.
- Garg, S.; Garg, P. K.; Zalutsky, M. R. *N*-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. *Bioconjugate Chem.* **1991**, *2*, 50–56.
- Davis, M. I.; Bennett, M. J.; Thomas, L. M.; Bjorkman, P. J. Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. *Proc. Natl. Acad. Sci. U.S.A.* **2005**, *102*, 5981–5986.
- Mesters, J. R.; Henning, K.; Hilgenfeld, R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2007**, *63*, 508–513.
- Barinka, C.; Starkova, J.; Konvalinka, J.; Lubkowski, J. A high-resolution structure of ligand-free human glutamate carboxypeptidase II. *Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun.* **2007**, *63*, 150–153.
- Barinka, C.; Hlouchova, K.; Rovenska, M.; Majer, P.; Dauter, M.; Hin, N.; Ko, Y. S.; Tsukamoto, T.; Slusher, B. S.; Konvalinka, J.; Lubkowski, J. Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. *J. Mol. Biol.* **2008**, *376*, 1438–1450.
- Wu, G.; Robertson, D. H.; Brooks, C. L., III; Vieth, M. Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. *J. Comput. Chem.* **2003**, *24*, 1549–1562.
- Chen, X.; Park, R.; Shahinian, A. H.; Tohme, M.; Khankaldyian, V.; Bozorgzadeh, M. H.; Bading, J. R.; Moats, R.; Laug, W. E.; Conti, P. S. ¹⁸F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. *Nucl. Med. Biol.* **2004**, *31*, 179–189.
- Lupold, S. E.; Hicke, B. J.; Lin, Y.; Coffey, D. S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. *Cancer Res.* **2002**, *62*, 4029–4033.
- Kozikowski, A. P.; Zhang, J.; Nan

- Pointner, J.; Reissigl, A.; McLeod, D. G.; Douglas, T.; Morgan, T.; Gilbaugh, J., Jr. Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. *Urology* **1998**, *51*, 89–97.
- (43) Galsky, M. D.; Eisenberger, M.; Moore-Cooper, S.; Kelly, W. K.; Slovin, S. F.; DeLaCruz, A.; Lee, Y.; Webb, I. J.; Scher, H. I. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. *J. Clin. Oncol.* **2008**, *26*, 2147–2154.
- (44) Vaidyanathan, G.; Zalutsky, M. R. Improved synthesis of *N*-succinimidyl 4-[¹⁸F]fluorobenzoate and its application to the labeling of a monoclonal antibody fragment. *Bioconjugate Chem.* **1994**, *5*, 352–356.
- (45) Vaidyanathan, G.; Zalutsky, M. R. Synthesis of *N*-succinimidyl 4-[¹⁸F]fluorobenzoate, an agent for labeling proteins and peptides with ¹⁸F. *Nat. Protoc.* **2006**, *1*, 1655–1661.
- (46) Marik, J.; Sutcliffe, J. L. Fully automated preparation of n.c.a. 4-[¹⁸F]fluorobenzoic acid and *N*-succinimidyl 4-[¹⁸F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU). *Appl. Radiat. Isot.* **2007**, *65*, 199–203.
- (47) Zijlstra, S.; Gunawan, J.; Burchert, W. Synthesis and evaluation of a ¹⁸F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. *Appl. Radiat. Isot.* **2003**, *58*, 201–207.
- (48) Dekker, B.; Keen, H.; Shaw, D.; Disley, L.; Hastings, D.; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. *Nucl. Med. Biol.* **2005**, *32*, 403–413.
- (49) Vaidyanathan, G.; Zalutsky, M. R. Labeling proteins with fluorine-18 using *N*-succinimidyl 4-[¹⁸F]fluorobenzoate. *Nucl. Med. Biol.* **1992**, *19*, 275–281.
- (50) Garg, S.; Garg, P. K.; Zhao, X. G.; Friedman, H. S.; Bigner, D. D.; Zalutsky, M. R. Radioiodination of a monoclonal antibody using *N*-succinimidyl 5-iodo-3-pyridinecarboxylate. *Nucl. Med. Biol.* **1993**, *20*, 835–842.
- (51) Garg, S.; Garg, P. K.; Zalutsky, M. R. *N*-Succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. *Bioconjugate Chem.* **1991**, *2*, 50–56.
- (52) Robinson, M. B.; Blakely, R. D.; Couto, R.; Coyle, J. T. Hydrolysis of the brain dipeptide *N*-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel *N*-acetylated alpha-linked acidic dipeptidase activity from rat brain. *J. Biol. Chem.* **1987**, *262*, 14498–14506.
- (53) Cheng, H. C. determination of KB or Ki from IC50. A closer look at the Cheng–Prusoff equation, the Schild plot and related power equations. *J. Pharmacol. Toxicol. Methods* **2001**, *46*, 61–71.

JM801055H